Pneumococcal capsular polysaccharide antigens and PF-07872411-engaged innate immune pathways

This target complex comprises the capsular polysaccharide antigens from multiple Streptococcus pneumoniae serotypes and the specific innate immune pathways activated by the investigational adjuvant PF-07872411. The polysaccharide antigens are the primary targets for the adaptive immune system, intended to elicit protective, serotype-specific antibodies that facilitate bacterial clearance through opsonophagocytosis [1, 3]. PF-07872411 is an immunostimulant designed to enhance the vaccine's immunogenicity by engaging innate immune pathways, typically involving pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) [7, 15]. By activating these pathways, the adjuvant promotes the maturation of dendritic cells and the secretion of cytokines, which in turn drives a more robust and durable T-cell and B-cell response [16, 24]. This dual-target approach is utilized in next-generation multivalent pneumococcal conjugate vaccines, such as PF-07872412, to provide broader protection against invasive pneumococcal diseases like pneumonia, meningitis, and sepsis [4, 6]. Clinical evaluation of this target system is currently focused on assessing the safety and immunologic synergy between the adjuvant and the multivalent antigen components [12, 14].

Other names

Pneumococcal conjugate vaccine antigensPF-07872411 adjuvant targetInnate immune pathwaysStreptococcus pneumoniae antigensPneumococcal capsular polysaccharides

Adjuvant-mediated activation of innate immune pathways (likely Toll-like receptors) to enhance the adaptive immune response against pneumococcal capsular polysaccharide antigens.